标题
How I treat CML blast crisis
作者
关键词
-
出版物
BLOOD
Volume 120, Issue 4, Pages 737-747
出版商
American Society of Hematology
发表日期
2012-06-01
DOI
10.1182/blood-2012-03-380147
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- HIF1 is required for survival maintenance of chronic myeloid leukemia stem cells
- (2012) H. Zhang et al. BLOOD
- Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias
- (2011) F. E. Nicolini et al. BLOOD
- Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV
- (2011) A. Fabarius et al. BLOOD
- BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
- (2011) S. Soverini et al. BLOOD
- Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
- (2011) B. Simonsson et al. BLOOD
- Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score
- (2011) J. Hasford et al. BLOOD
- The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
- (2011) E. Jabbour et al. BLOOD
- Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression
- (2011) C. M. Lucas et al. BLOOD
- Is carcinogenesis a form of speciation?
- (2011) Peter Duesberg et al. CELL CYCLE
- Treatment of chronic myeloid leukemia when imatinib fails
- (2011) Rüdiger Hehlmann et al. EXPERT OPINION ON PHARMACOTHERAPY
- Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
- (2011) Rüdiger Hehlmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
- (2011) David Marin et al. JOURNAL OF CLINICAL ONCOLOGY
- BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia
- (2011) Christian Hurtz et al. JOURNAL OF EXPERIMENTAL MEDICINE
- p53 stabilization induces apoptosis in chronic myeloid leukemia blast crisis cells
- (2011) L F Peterson et al. LEUKEMIA
- Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors
- (2011) D H Mak et al. LEUKEMIA
- The MEK inhibitor PD184352 enhances BMS-214662-induced apoptosis in CD34+ CML stem/progenitor cells
- (2011) F Pellicano et al. LEUKEMIA
- Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
- (2011) F J Giles et al. LEUKEMIA
- A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases
- (2011) V Grossmann et al. LEUKEMIA
- BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition
- (2011) Cihangir Duy et al. NATURE
- Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib
- (2010) Baijun Fang et al. ANNALS OF HEMATOLOGY
- Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
- (2010) E. Jabbour et al. BLOOD
- Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)
- (2010) T. P. Hughes et al. BLOOD
- The EBMT activity survey 2008: impact of team size, team density and new trends
- (2010) A Gratwohl et al. BONE MARROW TRANSPLANTATION
- Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study
- (2010) Giuseppe Saglio et al. CANCER
- Chronic myeloid leukemia: mechanisms of blastic transformation
- (2010) Danilo Perrotti et al. JOURNAL OF CLINICAL INVESTIGATION
- Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial
- (2010) François-Xavier Mahon et al. LANCET ONCOLOGY
- Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia
- (2010) Claude Preudhomme et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
- (2010) Giuseppe Saglio et al. NEW ENGLAND JOURNAL OF MEDICINE
- Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein
- (2010) M. Jaras et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Current role of stem cell transplantation in chronic myeloid leukaemia
- (2009) Alois Gratwohl et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- The blast phase of chronic myeloid leukaemia
- (2009) Richard T. Silver BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors
- (2009) S. Soverini et al. BLOOD
- Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV
- (2009) S. Saussele et al. BLOOD
- The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data
- (2009) V. G. Oehler et al. BLOOD
- Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance
- (2009) D. Verma et al. BLOOD
- Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
- (2009) Michele Baccarani et al. JOURNAL OF CLINICAL ONCOLOGY
- Similar patterns of chromosome abnormalities in CML occur in addition to the Philadelphia chromosome with or without tyrosine kinase inhibitor treatment
- (2009) C Haferlach et al. LEUKEMIA
- Harmonization of molecular monitoring of CML therapy in Europe
- (2009) M C Müller et al. LEUKEMIA
- Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells
- (2009) D. H. Mak et al. MOLECULAR CANCER THERAPEUTICS
- Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia
- (2009) Chen Zhao et al. NATURE
- Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma
- (2009) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia
- (2008) K. Porkka et al. BLOOD
- RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance
- (2008) C. Roche-Lestienne et al. BLOOD
- A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo
- (2008) L. C. Cerchietti et al. BLOOD
- Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation
- (2008) Christine Dierks et al. CANCER CELL
- Specific clones of spontaneously evolving karyotypes generate individuality of cancers
- (2008) Alice Fabarius et al. CANCER GENETICS AND CYTOGENETICS
- Treatment of chronic myeloid leukemia in blast crisis
- (2008) R. Hehlmann et al. HAEMATOLOGICA
- Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up
- (2008) F. Palandri et al. HAEMATOLOGICA
- Experimental non-ATP-competitive therapies for chronic myelogenous leukemia
- (2008) A Quintás-Cardama LEUKEMIA
- Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase
- (2008) J Cortes et al. LEUKEMIA
- BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
- (2008) Charles G. Mullighan et al. NATURE
- Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous Leukemia
- (2008) Francis J. Giles et al. SEMINARS IN ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started